<?xml version="1.0" encoding="UTF-8"?>
<ref id="hep41480-bib-0024">
 <label>24</label>
 <mixed-citation publication-type="journal" id="hep41480-cit-0024">
  <string-name>
   <surname>Poordad</surname>
   <given-names>F</given-names>
  </string-name>, 
  <string-name>
   <surname>Schiff</surname>
   <given-names>ER</given-names>
  </string-name>, 
  <string-name>
   <surname>Vierling</surname>
   <given-names>JM</given-names>
  </string-name>, 
  <string-name>
   <surname>Landis</surname>
   <given-names>C</given-names>
  </string-name>, 
  <string-name>
   <surname>Fontana</surname>
   <given-names>RJ</given-names>
  </string-name>, 
  <string-name>
   <surname>Yang</surname>
   <given-names>R</given-names>
  </string-name>, et al. 
  <article-title>Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence</article-title>. 
  <source xml:lang="en">Hepatology</source>
  <year>2016</year>;
  <volume>63</volume>:
  <fpage>1493</fpage>‐
  <lpage>1505</lpage>.
  <pub-id pub-id-type="pmid">26754432</pub-id>
 </mixed-citation>
</ref>
